Cargando…

PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker

PURPOSE: To estimate the therapeutic potential of PD-L1 inhibition in breast cancer, we evaluated the prevalence and significance of PD-L1 protein expression with a validated antibody and CD274 gene alternation in a large cohort of triple negative breast cancer (TNBC) and correlated with clinicopath...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Lei, Li, Wenbin, Zhu, Xinxin, Ling, Yun, Qiu, Tian, Dong, Lin, Fang, Yi, Yang, Hongying, Ying, Jianming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916110/
https://www.ncbi.nlm.nih.gov/pubmed/27390646
http://dx.doi.org/10.1186/s40064-016-2513-x
_version_ 1782438773476294656
author Guo, Lei
Li, Wenbin
Zhu, Xinxin
Ling, Yun
Qiu, Tian
Dong, Lin
Fang, Yi
Yang, Hongying
Ying, Jianming
author_facet Guo, Lei
Li, Wenbin
Zhu, Xinxin
Ling, Yun
Qiu, Tian
Dong, Lin
Fang, Yi
Yang, Hongying
Ying, Jianming
author_sort Guo, Lei
collection PubMed
description PURPOSE: To estimate the therapeutic potential of PD-L1 inhibition in breast cancer, we evaluated the prevalence and significance of PD-L1 protein expression with a validated antibody and CD274 gene alternation in a large cohort of triple negative breast cancer (TNBC) and correlated with clinicopathological data and patients overall survival. METHODS: Immunohistochemistry and in situ mRNA hybridization was used to detect PD-L1 protein and mRNA expression in tumor tissues from 183 TNBC patients respectively. Fluorescence in situ hybridization analysis was performed on PD-L1 strong expression samples to assess copy number on chromosome 9p24.1 of CD274 gene. RESULTS: Expression of PD-L1 by immune cells was observed in 4.9 % of TNBC, while expression by tumor cells accounted for 8.7 %. There was a high concordance in PD-L1 protein expression and PDL1 mRNA expression. Samples with PD-L1 strong expression were found to have a CD274 gene copy number gain. PD-L1 expression was correlated with higher tumor grade, but was independent of menopausal status, lymph nodes metastasis, histological subtype and tumor size. In addition, we used precise stratification of PD-L1 expression on tumor or immune cells of certain breast cancer subtype and suggested that patients with PD-L1 expression in basal-like tumors by immune cells or with CD274 gene copy number gain had a longer disease-specific overall survival. CONCLUSIONS: Our findings may promote the more precise analysis of PD-L1 expression in breast cancer and aid the selection of patients who may benefit from immune therapy.
format Online
Article
Text
id pubmed-4916110
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-49161102016-07-07 PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker Guo, Lei Li, Wenbin Zhu, Xinxin Ling, Yun Qiu, Tian Dong, Lin Fang, Yi Yang, Hongying Ying, Jianming Springerplus Research PURPOSE: To estimate the therapeutic potential of PD-L1 inhibition in breast cancer, we evaluated the prevalence and significance of PD-L1 protein expression with a validated antibody and CD274 gene alternation in a large cohort of triple negative breast cancer (TNBC) and correlated with clinicopathological data and patients overall survival. METHODS: Immunohistochemistry and in situ mRNA hybridization was used to detect PD-L1 protein and mRNA expression in tumor tissues from 183 TNBC patients respectively. Fluorescence in situ hybridization analysis was performed on PD-L1 strong expression samples to assess copy number on chromosome 9p24.1 of CD274 gene. RESULTS: Expression of PD-L1 by immune cells was observed in 4.9 % of TNBC, while expression by tumor cells accounted for 8.7 %. There was a high concordance in PD-L1 protein expression and PDL1 mRNA expression. Samples with PD-L1 strong expression were found to have a CD274 gene copy number gain. PD-L1 expression was correlated with higher tumor grade, but was independent of menopausal status, lymph nodes metastasis, histological subtype and tumor size. In addition, we used precise stratification of PD-L1 expression on tumor or immune cells of certain breast cancer subtype and suggested that patients with PD-L1 expression in basal-like tumors by immune cells or with CD274 gene copy number gain had a longer disease-specific overall survival. CONCLUSIONS: Our findings may promote the more precise analysis of PD-L1 expression in breast cancer and aid the selection of patients who may benefit from immune therapy. Springer International Publishing 2016-06-21 /pmc/articles/PMC4916110/ /pubmed/27390646 http://dx.doi.org/10.1186/s40064-016-2513-x Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research
Guo, Lei
Li, Wenbin
Zhu, Xinxin
Ling, Yun
Qiu, Tian
Dong, Lin
Fang, Yi
Yang, Hongying
Ying, Jianming
PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
title PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
title_full PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
title_fullStr PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
title_full_unstemmed PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
title_short PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
title_sort pd-l1 expression and cd274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916110/
https://www.ncbi.nlm.nih.gov/pubmed/27390646
http://dx.doi.org/10.1186/s40064-016-2513-x
work_keys_str_mv AT guolei pdl1expressionandcd274genealterationintriplenegativebreastcancerimplicationforprognosticbiomarker
AT liwenbin pdl1expressionandcd274genealterationintriplenegativebreastcancerimplicationforprognosticbiomarker
AT zhuxinxin pdl1expressionandcd274genealterationintriplenegativebreastcancerimplicationforprognosticbiomarker
AT lingyun pdl1expressionandcd274genealterationintriplenegativebreastcancerimplicationforprognosticbiomarker
AT qiutian pdl1expressionandcd274genealterationintriplenegativebreastcancerimplicationforprognosticbiomarker
AT donglin pdl1expressionandcd274genealterationintriplenegativebreastcancerimplicationforprognosticbiomarker
AT fangyi pdl1expressionandcd274genealterationintriplenegativebreastcancerimplicationforprognosticbiomarker
AT yanghongying pdl1expressionandcd274genealterationintriplenegativebreastcancerimplicationforprognosticbiomarker
AT yingjianming pdl1expressionandcd274genealterationintriplenegativebreastcancerimplicationforprognosticbiomarker